Arno Therapeutics Submits IMPD to French Health Authority to Initiate Phase I Trial of Onapristone in PR Positive Tumors

Published: Sep 09, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

FLEMINGTON, N.J., Sept. 9, 2013 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced it has submitted an Investigational Medicinal Product Dossier (IMPD) to the French Health Authority, L'Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM), to request the clinical trial authorization of a Phase I dose escalation study evaluating Arno's lead compound onapristone in progesterone receptor positive tumors in post-menopausal women. Arno expects to initiate the Phase I trial in the fourth quarter of this year.

Help employers find you! Check out all the jobs and post your resume.

Back to news